190 related articles for article (PubMed ID: 16978870)
1. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.
Ryan AB; Zeitlin SO; Scrable H
Neurobiol Dis; 2006 Nov; 24(2):419-27. PubMed ID: 16978870
[TBL] [Abstract][Full Text] [Related]
2. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
3. p53 tumor suppressor protein regulates the levels of huntingtin gene expression.
Feng Z; Jin S; Zupnick A; Hoh J; de Stanchina E; Lowe S; Prives C; Levine AJ
Oncogene; 2006 Jan; 25(1):1-7. PubMed ID: 16278683
[TBL] [Abstract][Full Text] [Related]
4. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.
Gu X; Greiner ER; Mishra R; Kodali R; Osmand A; Finkbeiner S; Steffan JS; Thompson LM; Wetzel R; Yang XW
Neuron; 2009 Dec; 64(6):828-40. PubMed ID: 20064390
[TBL] [Abstract][Full Text] [Related]
5. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
7. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
Sadri-Vakili G; Menon AS; Farrell LA; Keller-McGandy CE; Cantuti-Castelvetri I; Standaert DG; Augood SJ; Yohrling GJ; Cha JH
Eur J Neurosci; 2006 Jun; 23(12):3171-5. PubMed ID: 16820007
[TBL] [Abstract][Full Text] [Related]
8. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
9. Mutant alleles of HD improve the life span of p53(-/-) mice.
Ryan A; Scrable H
Mech Ageing Dev; 2008 Apr; 129(4):238-41. PubMed ID: 18242663
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of neurodegeneration in Huntington's disease.
Gil JM; Rego AC
Eur J Neurosci; 2008 Jun; 27(11):2803-20. PubMed ID: 18588526
[TBL] [Abstract][Full Text] [Related]
11. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity.
Luo S; Vacher C; Davies JE; Rubinsztein DC
J Cell Biol; 2005 May; 169(4):647-56. PubMed ID: 15911879
[TBL] [Abstract][Full Text] [Related]
12. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
13. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
14. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis.
Passani LA; Bedford MT; Faber PW; McGinnis KM; Sharp AH; Gusella JF; Vonsattel JP; MacDonald ME
Hum Mol Genet; 2000 Sep; 9(14):2175-82. PubMed ID: 10958656
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice.
Oliveira JM; Jekabsons MB; Chen S; Lin A; Rego AC; Gonçalves J; Ellerby LM; Nicholls DG
J Neurochem; 2007 Apr; 101(1):241-9. PubMed ID: 17394466
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
17. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.
Benn CL; Luthi-Carter R; Kuhn A; Sadri-Vakili G; Blankson KL; Dalai SC; Goldstein DR; Spires TL; Pritchard J; Olson JM; van Dellen A; Hannan AJ; Cha JH
J Neuropathol Exp Neurol; 2010 Aug; 69(8):817-27. PubMed ID: 20613636
[TBL] [Abstract][Full Text] [Related]
18. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
19. Mouse Huntington's disease homolog mRNA levels: variation and allele effects.
Dixon KT; Cearley JA; Hunter JM; Detloff PJ
Gene Expr; 2004; 11(5-6):221-31. PubMed ID: 15200234
[TBL] [Abstract][Full Text] [Related]
20. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
